|Videos|April 9, 2013
Episode 13- Current Developments of Pharmacotherapeutic Spending
Advertisement
Episodes in this series
During this segment, David Calabrese, RPh, MHP, explores the current trends of pharmacotherapeutic spending for the treatment of chronic conditions.
Mr Calabrese explains that from a research and developmental stage, there has been a stronger trend toward investing within the specialty market, rather than on traditional products.
Over 30 new products have been approved in the United States over the past year, and this number is expected to continue to grow annually. For this reason, investors seem more interested in supporting today’s higher-cost, complex therapies rather than traditional products for the treatment of chronic conditions.
Advertisement
Related to this article
The editor in chief of Evidence-Based Oncology, who was recently named medical director of Precision Medicine for The US Oncology Network, discussed milestones met and those still to be achieved.
Alice Hall-Partyka, JD, a partner at Crowell & Moring explains the lawsuits challenging CMS' Medicaid rule on pediatric gender care and its legal weak points.
Siva Mohan, MD, explains how drug costs drive silent nonadherence, PA burden, and biosimilar hesitancy, and what payers can do about it.
In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting possible substitution.
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
MedHaul’s platform streamlines nonemergency medical transportation, boosting on-time oncology visits, reducing costs, and helping patients reach critical care across underserved regions.
CMS' rule ending Medicaid and CHIP funding for pediatric sex-rejecting procedures is now in effect.
Advertisement
Advertisement